Robin Feldman is the Arthur J. Goldberg Distinguished Professor of Law and Director of the UC Hastings Center for Innovation. Her work focuses on the role of intellectual property law in technology and innovation, drug pricing and health care law, and artificial intelligence and data.
Feldman has published four books, Drugs, Money, & Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices (Cambridge 2019); Drug Wars: How Big Pharma Raises Prices & Keeps Generics Off the Market (Cambridge 2017), Rethinking Patent Law (Harvard 2012) and The Role of Science in Law (Oxford 2009). She has published more than 50 articles in law journals, including at Harvard, Yale, and Stanford, in The New England Journal of Medicine, and in the American Economic Review. Her op-ed articles have appeared in the New York Times, Washington Post, Boston Globe, San Francisco Chronicle, The Hill, and many others.
Professor Feldman’s work has been cited extensively by the White House, numerous federal and state agencies, and members of Congress. Her IP/Antitrust work was cited by both sides during a recent Supreme Court case. She has appeared frequently before committees of the US House & Senate, the California legislature, and federal agencies such as the FTC, DOJ, USPTO, and the National Academy of Sciences. She participated in the GAO’s report to Congress on Artificial Intelligence and in the Army Cyber Institute’s threat casting exercise on weaponization of data. She is also an elected member and appointed advisor to the American Law Institute’s Restatement of Copyright Project.
[SHARE]
Expert DirectLink
-
We need a labeling system for pharmaceutical prices
The Washington Post [June 10, 2022] -
Understanding ‘Evergreening’: Making Minor Modifications of Existing Medications to Extend Protections
Health Affairs Journal [May 17, 2022] -
Challenges with Defining Pharmaceutical Markets and Potential Remedies to Screen for Industry Consolidation
Journal of Health Politics, Policy and Law [May 6, 2022] -
A Patient Price Guide for Prescription Medicine (by Robin Feldman, Natalie Feldman, Enrique Seoane-Vazquez)
Annals of Internal Medicine [March 22, 2022] -
The Price Tag of Pay-for-Delay
Columbia University’s Science and Technology Law Review [March 7, 2022] -
The Burden on Society from Eleventh-Hour 'Citizen Petitions' Field to Slow Generic Drugs
Maryland Law Review Online [October 21, 2019] -
Naked Price and Pharmaceutical Trade Secret Overreach
Yale Journal of Law & Technology [Forthcoming] -
Drugs, Money, and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices
Cambridge University Press [2019] -
The Devil is in the Tiers (Drug pricing)
SSRN [2019] -
Artificial Intelligence: The Importance of Trust & Distrust
Green Bag, Volume 21, No. 3 [2018] -
May Your Drug Price be Evergreen
Journal Law and the Biosciences [2018] -
Drug Wars: How Big Pharma Raises Prices & Keeps Generics Off the Market
Cambridge University Press [2017] -
Patent Demands and Initial Public Offerings
Stanford Technology Law Review [2015] -
Rethinking Patent Law
Harvard University Press [2012] -
Patent Licensing, Technology Transfer and Innovation
American Economic Review [https://www.aeaweb.org/articles?id=10.1257/aer.p20161092]















